CA2645731A1 - N-substituted-azacyclylamines as histamine-3 antagonists - Google Patents

N-substituted-azacyclylamines as histamine-3 antagonists Download PDF

Info

Publication number
CA2645731A1
CA2645731A1 CA002645731A CA2645731A CA2645731A1 CA 2645731 A1 CA2645731 A1 CA 2645731A1 CA 002645731 A CA002645731 A CA 002645731A CA 2645731 A CA2645731 A CA 2645731A CA 2645731 A1 CA2645731 A1 CA 2645731A1
Authority
CA
Canada
Prior art keywords
methyl
benzimidazol
benzoyl
bipyrrolidine
pyrrolidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002645731A
Other languages
English (en)
French (fr)
Inventor
Derek Cecil Cole
Magda Asselin
Joseph Raymond Stock
Albert Jean Robichaud
Ji-In Kim
William Ronald Solvibile Jr.
Jonathan Laird Gross
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2645731A1 publication Critical patent/CA2645731A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA002645731A 2006-03-15 2007-03-08 N-substituted-azacyclylamines as histamine-3 antagonists Abandoned CA2645731A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US78251306P 2006-03-15 2006-03-15
US60/782,513 2006-03-15
US85907906P 2006-11-15 2006-11-15
US60/859,079 2006-11-15
PCT/US2007/005776 WO2007108936A2 (en) 2006-03-15 2007-03-08 N-substituted-azacyclylamines as histamine-3 antagonists

Publications (1)

Publication Number Publication Date
CA2645731A1 true CA2645731A1 (en) 2007-09-27

Family

ID=38353957

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002645731A Abandoned CA2645731A1 (en) 2006-03-15 2007-03-08 N-substituted-azacyclylamines as histamine-3 antagonists

Country Status (11)

Country Link
US (1) US7820825B2 (https=)
EP (1) EP1994022A2 (https=)
JP (1) JP2009530274A (https=)
AR (1) AR059905A1 (https=)
AU (1) AU2007227681A1 (https=)
BR (1) BRPI0709612A2 (https=)
CA (1) CA2645731A1 (https=)
MX (1) MX2008011791A (https=)
PE (1) PE20071023A1 (https=)
TW (1) TW200800958A (https=)
WO (1) WO2007108936A2 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005230902A1 (en) * 2004-03-31 2005-10-20 Janssen Pharmaceutica, N.V. Non-imidazole heterocyclic compounds as histamine H3-receptor ligands
BRPI0709612A2 (pt) 2006-03-15 2011-07-19 Wyeth Corp composto de fórmula i; método para o tratamento de um distúrbio no sistema nervoso central relacionado ou afetado pelo receptor histamina-3 em um paciente que necessita deste tratamento; método para a inibição do receptor h3; composição farmacêutica; e processo para a preparação de um composto de fórmula i
EP2027086B1 (en) 2006-05-19 2011-11-16 Wyeth LLC N-benzoyl-pyrrolidin-3-ylamines as histamine-3 antagonists
EA015555B1 (ru) * 2006-05-30 2011-08-30 Янссен Фармацевтика Н.В. Замещенные пиридиламидные соединения в качестве модуляторов гистаминового h-рецептора
JP2009542706A (ja) * 2006-06-29 2009-12-03 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ヒスタミンh3受容体の置換ベンズアミドモジュレーター
PE20081152A1 (es) 2006-10-06 2008-08-10 Wyeth Corp Azaciclilaminas n-sustituidas como antagonistas de histamina-3
TW200823204A (en) * 2006-10-17 2008-06-01 Arena Pharm Inc Biphenyl sulfonyl and phenyl-heteroaryl sulfonyl modulators of the histamine H3-receptor useful for the treatment of disorders related thereto
TW200901983A (en) * 2007-05-24 2009-01-16 Wyeth Corp Azacyclylbenzamide derivatives as histamine-3 antagonists
CA2693138A1 (en) 2007-07-16 2009-01-22 Wyeth Llc Aminoalkylazole derivatives as histamine-3 antagonists
EP2220045A1 (en) * 2007-11-20 2010-08-25 Janssen Pharmaceutica, N.V. Substituted pyridyl amide compounds as modulators of the histamine h3 receptor
EA018582B1 (ru) 2007-11-20 2013-09-30 Янссен Фармацевтика Н.В. Соединения циклоалкилокси- и гетероциклоалкилоксипиридина как модуляторы гистаминового рецептора н
AU2010264422B2 (en) * 2009-06-26 2014-12-18 Sanofi Novel fumarate salts of a histamine H3 receptor antagonist
WO2012102254A1 (ja) 2011-01-25 2012-08-02 キッセイ薬品工業株式会社 インドール誘導体、またはその薬理学的に許容される塩
KR102127939B1 (ko) 2012-07-17 2020-06-29 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 선택적인 안드로겐 수용체 조절제로서의 인돌카르보니트릴
DK3307734T3 (da) 2015-06-09 2020-01-27 Abbvie Inc Nukleære receptormodulatorer (ror) til behandling af inflammatoriske og autoimmune sygdomme
WO2020113094A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1416872A (en) 1972-03-10 1975-12-10 Wyeth John & Brother Ltd 4-aminoquinoline derivatives
US3933829A (en) 1974-08-22 1976-01-20 John Wyeth & Brother Limited 4-Aminoquinoline derivatives
US4166853A (en) 1978-05-05 1979-09-04 The Upjohn Company Antihypertensive 7-trifluoromethyl-4-aminoquinolones
US4159331A (en) 1978-05-05 1979-06-26 The Upjohn Company Antihypertensive 4-aminoquinolines
EP0525129A4 (en) 1990-04-13 1993-03-24 Smith-Kline Beecham Corporation Substituted benzimidazoles
ATE219766T1 (de) 1993-04-07 2002-07-15 Otsuka Pharma Co Ltd N-acylierte 4-aminopiperidin derivate als aktive bestandteile von peripher gefässerweiternden wikstoffen
IL117149A0 (en) 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
US6034093A (en) * 1995-06-07 2000-03-07 Rhone-Poulenc Rorer Pharmaceuticals Inc. Substituted sulfonic acid N-[(aminoiminomethyl)phenylalkyl]-azaheterocyclylamide compounds
US6541499B1 (en) 1997-05-01 2003-04-01 Eli Lilly And Company Antithrombotic agents
US7375125B2 (en) * 1999-08-04 2008-05-20 Ore Pharmaceuticals, Inc. Melanocortin-4 receptor binding compounds and methods of use thereof
US6699873B1 (en) * 1999-08-04 2004-03-02 Millennium Pharmaceuticals, Inc. Melanocortin-4 receptor binding compounds and methods of use thereof
AU1734401A (en) 1999-12-09 2001-06-18 Mitsubishi Pharma Corporation Carboxyamido derivatives
WO2001074773A2 (en) 2000-03-31 2001-10-11 Ortho Mcneil Pharmaceutical, Inc. Phenyl-substituted indoles as histamine h3-receptor antagonists
US20070004713A1 (en) 2000-12-07 2007-01-04 Bernard Barlaam Therapeutic benimidazole compounds
HN2002000156A (es) 2001-07-06 2003-11-27 Inc Agouron Pharmaceuticals Derivados de benzamida tiazol y composiciones farmaceuticas para inhibir la proliferacion de celulas y metodos para su utilización.
NZ535985A (en) 2002-03-29 2007-04-27 Chiron Corp Substituted benzazoles and use thereof as RAF kinase inhibitors
EP2284172A1 (en) 2003-03-14 2011-02-16 MediGene Ltd. Immunomodulating heterocyclic compounds
SI1735278T1 (sl) * 2004-04-01 2010-05-31 Lilly Co Eli Agenti histamin h receptorja priprava in terapevtska uporaba
ES2540987T3 (es) 2004-05-14 2015-07-15 Millennium Pharmaceuticals, Inc. Métodos para preparar inhibidores de la aurora cinasa
TW200602314A (en) 2004-05-28 2006-01-16 Tanabe Seiyaku Co A novel pyrrolidine compound and a process for preparing the same
US20060014733A1 (en) * 2004-07-19 2006-01-19 Pfizer Inc Histamine-3 agonists and antagonists
DK1786790T3 (da) 2004-07-26 2009-07-20 Lilly Co Eli Oxazolderivater som histamin H3 receptorstoffer, fremstilling og terapeutiske anvendelser
ES2534605T3 (es) 2004-08-23 2015-04-24 Eli Lilly And Company Agentes receptores de la histamina H3, preparación y usos terapéuticos
CA2579889A1 (en) * 2004-09-09 2006-03-16 Astellas Pharma Inc. Thiazole derivatives having vap-1 inhibitory activity
UY29149A1 (es) 2004-10-07 2006-05-31 Boehringer Ingelheim Int Tiazolil-dihidro-indazoles
US7381732B2 (en) 2004-10-26 2008-06-03 Bristol-Myers Squibb Company Pyrazolobenzamides and derivatives as factor Xa inhibitors
CN101107231A (zh) 2005-01-21 2008-01-16 先灵公司 用作组胺h3拮抗剂的咪唑和苯并咪唑衍生物
US20070032475A1 (en) 2005-04-15 2007-02-08 Ye Xiaocong M Novel compounds useful for bradykinin B1 receptor antagonism
BRPI0709612A2 (pt) 2006-03-15 2011-07-19 Wyeth Corp composto de fórmula i; método para o tratamento de um distúrbio no sistema nervoso central relacionado ou afetado pelo receptor histamina-3 em um paciente que necessita deste tratamento; método para a inibição do receptor h3; composição farmacêutica; e processo para a preparação de um composto de fórmula i
CA2646585A1 (en) 2006-03-20 2007-09-27 Glaxo Group Limited Compounds which potentiate ampa receptor and uses thereof in medicine
US20070238718A1 (en) 2006-04-06 2007-10-11 Matthias Grauert Thiazolyl-dihydro-indazole
EP2027086B1 (en) * 2006-05-19 2011-11-16 Wyeth LLC N-benzoyl-pyrrolidin-3-ylamines as histamine-3 antagonists
PE20081152A1 (es) * 2006-10-06 2008-08-10 Wyeth Corp Azaciclilaminas n-sustituidas como antagonistas de histamina-3

Also Published As

Publication number Publication date
US20070219240A1 (en) 2007-09-20
JP2009530274A (ja) 2009-08-27
WO2007108936A3 (en) 2007-11-01
TW200800958A (en) 2008-01-01
AR059905A1 (es) 2008-05-07
BRPI0709612A2 (pt) 2011-07-19
AU2007227681A1 (en) 2007-09-27
EP1994022A2 (en) 2008-11-26
US7820825B2 (en) 2010-10-26
PE20071023A1 (es) 2007-10-03
MX2008011791A (es) 2008-09-25
WO2007108936A2 (en) 2007-09-27

Similar Documents

Publication Publication Date Title
US7820825B2 (en) N-substituted-azacyclylamines as histamine-3 antagonists
EP2074088A2 (en) N-substituted-azacyclylamines as histamine-3 antagonists
EP0666858B1 (en) 5-arylindole derivatives and their use as serotonin (5-ht 1) agonists
US7842715B2 (en) N-benzoyl- and N-benzylpyrrolidin-3-ylamines as histamine-3 antagonists
CN101356174B (zh) 吲哚-3-基-羰基-螺-哌啶衍生物
AU2005254658A1 (en) Indole derivatives as histamine receptor antagonists
SK50895A3 (en) 3-indolylpiperidine derivative, method of its preparation, its use for preparation of pharmaceutical composition and pharmaceutical composition containing them
JP2009501185A (ja) V1a受容体アンタゴニストとしてのインドール−3−イル−カルボニル−スピロ−ピペリジン誘導体
AU2008256803A1 (en) Azacyclylbenzamide derivatives as histamine-3 antagonists
CA2751402A1 (en) Substituted indole compounds as bradykinin receptor 1 modulators
CN101426778A (zh) 作为组胺-3拮抗剂的n-经取代-氮杂环基胺
US12540130B2 (en) Substituted pyrrolidine amides IV
JP2010090067A (ja) 含窒素複素環誘導体
CN101679276A (zh) 用作nk3拮抗剂的异喹啉酮衍生物
AU2009315761A1 (en) Quinazoline derivatives as NK3 receptor antagonists
CN101277945A (zh) 吲哚-3-基-羰基-哌啶和哌嗪衍生物
HK1142068A (en) Isoquinolinone derivatives as nk3 antagonists

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead

Effective date: 20130308